Solasia Pharma K.K.

DB:9SO Stock Report

Market Cap: €51.9m

Solasia Pharma K.K Management

Management criteria checks 2/4

Solasia Pharma K.K's CEO is Yoshihiro Arai, appointed in Feb 2013, has a tenure of 11.83 years. directly owns 0.53% of the company’s shares, worth €275.33K. The average tenure of the management team and the board of directors is 3.9 years and 7.2 years respectively.

Key information

Yoshihiro Arai

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure11.8yrs
CEO ownership0.5%
Management average tenure3.9yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

CEO

Yoshihiro Arai (64 yo)

11.8yrs

Tenure

Mr. Yoshihiro Arai has been the President, Chief Executive Officer and Representative Director at Solasia Pharma KK since February 2013. Mr. Arai served as Executive Vice President of Development of Solasi...

Leadership Team

NamePositionTenureCompensationOwnership
Yoshihiro Arai
President11.8yrsno data0.53%
€ 275.3k
Toshio Miyashita
CFO, GM of Management Headquarters & Director10.9yrsno data0.23%
€ 118.6k
Yasumitsu Shimada
Accounting Managerno datano datano data
Yasuaki Manabe
Head of Marketing Division4.9yrsno datano data
Fumiko Nagahama
Head of Product Development Divisionno datano datano data
Hikaru Osawa
Head of Production Management Division2.9yrsno datano data
Wataru Kobayashi
Head of Reliability Assurance Division2.9yrsno datano data
Kozo Yao
Head of Business Development Divisionless than a yearno datano data

3.9yrs

Average Tenure

Experienced Management: 9SO's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yoshihiro Arai
President11.8yrsno data0.53%
€ 275.3k
Toshio Miyashita
CFO, GM of Management Headquarters & Director9yrsno data0.23%
€ 118.6k
Yoshiyuki Yamakawa
Outside Audit & Supervisory Board Member4.8yrsno datano data
Stanley Lau
Independent Outside Director10yrsno datano data
Norikazu Eiki
Independent Outside Director8.7yrsno datano data
Susumu Araki
Full-time Outside Audit & Supervisory Board Member5.8yrsno datano data
Jiro Mizukawa
Independent Outside Director4.8yrsno datano data
Nagisa Kawaida
Outside Audit & Supervisory Board Memberless than a yearno datano data

7.2yrs

Average Tenure

67yo

Average Age

Experienced Board: 9SO's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Solasia Pharma K.K. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nobumasa MorimotoMizuho Securities Co., Ltd.
Kyoichiro ShigemuraNomura Securities Co. Ltd.
Dion Stéfan BüchnerPathology Associates Co., Ltd.